Physiologic/Pharmacologic Topical Cholinergic,Modulation of Retinal Disease (Evidence Against a Purely Optical Mechanism)

Methods

This retrospective observational study analyzed 29 consecutive patients (34 eyes) treated with topical acetylcholinesterase inhibition between 1999 and January 2001.¹  Visual acuity (Snellen) and near vision were recorded at baseline and at serial follow-up intervals.  The study was conducted in parallel with a separate investigation of seven consecutive patients receiving cholinergic modulation for presbyopia between 1998 and September 2000.²

Etiologies included dry and wet AMD, macular hole, solar retinopathy, Leber’s congenital amaurosis, diabetic retinopathy with maculopathy, and retinal vascular occlusion.  All patients demonstrated measurable restoration of vision.

Treatment protocol: Echothiophate iodide 0.30%, the lowest commercially available concentration at the time, was administered topically at bedtime, once weekly, to the worse eye initially.

Observed pharmacologic and physiologic properties:

• Timing requirement: The medication was administered at bedtime and required a minimum of six hours of uninterrupted sleep for efficacy; otherwise, the treatment effect was lost.
• Bilateral (crossover) effect: Unilateral administration produced bilateral improvement in visual function and miosis in the contralateral untreated eye.
• Duration of effect: A single bedtime application produced up to one week of visual improvement - exceeding the expected pharmacokinetic duration of the drug.
• Dose sensitivity: The therapeutic effect was observed at concentrations as low as 0.0025% and was lost at concentrations above 0.03%.
• Resistance to reversal: Vision restoration persisted despite pharmacologic reversal of miosis with topical phenylephrine 10% or tropicamide applied one to two days post-treatment.
• Reversibility: Discontinuation of therapy resulted in loss of visual gains approximately six days after the last dose.  Patients 5 and 9 voluntarily discontinued treatment and lost the effect.  Patient 12, who applied the medication in the morning rather than at bedtime, also lost benefit; however, partial vision restoration returned upon resuming proper bedtime dosing.
• Partial recovery after reinitiation: Partial restoration of vision was commonly observed upon restarting therapy after cessation.

Below is a table of visual outcomes for all 29 patients listing by patient number, diagnosis, baseline vision and final vision.  This listing does not reflect the chronological order of patients.  Patient 12 with geographic atrophy Dry AMD was the first patient.  Patient 29 was mid series.

Table. Visual Outcomes in 29 Patients Treated with Topical Acetylcholinesterase Inhibitor
Adapted from US Patent 6,605,640 B2)

Patient No.	Lens Status	Diagnosis	Baseline VA	Final / Best VA	Notes
1	Pseudophakic	Wet AMD	CF (~20/400)	20/200	Gradual improvement
2	Pseudophakic	Dry AMD	20/40	20/30	Stable gain
3	Pseudophakic	Retinal vascular occlusion	CF (~20/400)	~20/400	Functional improvement
4	Pseudophakic	Dry AMD	20/70	20/40	Improved near vision
5	Pseudophakic	Dry AMD + preretinal fibrosis	20/50	20/30	Temporary discontinuation reduced effect
6	Pseudophakic	Dry AMD (s/p wet AMD laser)	20/25	20/20	Rapid response
7	Pseudophakic	Early AMD	20/30	20/15	Marked improvement
8	Phakic	Dry AMD	20/25	20/15	Rapid improvement
9	Pseudophakic	Dry AMD	CF	20/200	Compliance-dependent
10	Phakic	Macular hole (OU)	~20/100	~20/70	Improved reading ability
11	Pseudophakic	Diabetic retinopathy w/ maculopathy	20/70	20/40	Stable after 6 weeks
12	Pseudophakic	Dry AMD	CF (~20/400)	20/300	Loss with AM dosing
13	Pseudophakic	Dry AMD	20/100	20/50	Early response
14	Pseudophakic	Dry AMD	20/100	20/40	Reduced effect with improper timing
15	Pseudophakic	Wet AMD (L), Dry AMD (R)	CF (L), 20/40 (R)	20/400 (L), 20/20 (R)	Bilateral response
16	Pseudophakic	Dry AMD (R), Wet AMD (L)	20/25 (R), 20/200 (L)	20/20 (R), 20/100 (L)	Asymmetric response
17	Phakic	Solar retinopathy	20/30	20/25	Maintained despite interruption
18	Pseudophakic	BRVO	20/400	20/100	Rapid early improvement
19	Phakic	Mild dry AMD	20/25	20/20	Mild gain
20	Pseudophakic	Dry AMD (OU)	~20/25	20/20	Bilateral improvement
21	Phakic	Leber congenital amaurosis	CF / LP	20/200	Significant gain
22	Phakic	Diabetic retinopathy	20/200	20/100	Bilateral treatment effect
23	Pseudophakic	AMD (post-Visudyne)	HM	~20/100	Peripheral improvement noted
24	Pseudophakic	Dry AMD	20/40	20/25	Reversible with compliance
25	Pseudophakic	Dry AMD + occult wet AMD	20/30	20/20	Sustained improvement
26	Pseudophakic	Dry AMD	20/30	20/20	Rapid response
27	Pseudophakic	Preretinal fibrosis	20/40	~20/40+	Minimal change
28	Phakic	Macular hole + mild AMD	CF (~20/400)	20/400	Limited response
29	Pseudophakic	Dry AMD (aniridia OS)	20/30 (R), 20/100 (L)	20/25 (R), 20/50 (L)	Bilateral improvement

This presentation will stress patient 29 who has aniridia, no pupil but has vision restoration without miosis

Patient 29, a pseudophakic individual with asymmetric dry AMD and unilateral aniridia (resulting from complicated cataract surgery in the mid-1970s and subsequent sulcus-fixated intraocular lens implantation in the late 1980s), was examined as a mechanistic control.  The absence of the iris excluded the possibility of pharmacologic miosis as a confounding factor.  Treatment was initiated unilaterally and later extended bilaterally.  Outcomes were monitored over a two-month period, confirming the presence of visual restoration despite the absence of pupillary function.

Discussion

The present findings suggest that physiologic and pharmacologic cholinergic modulation can improve visual function in patients with outer retinal disease through mechanisms extending beyond simple optical effects.  A central question is whether the observed improvements are primarily due to miosis-induced enhancement of depth of focus or whether they reflect modulation of retinal and central neural processing.  The results of this study, including reversal of miosis with phenylephrine 10% and the documented improvement in the aniridic Patient 29, argue strongly against a purely optical mechanism.

Patient 29 serves as a critical internal control.  This pseudophakic individual with asymmetric dry AMD experienced substantial improvement in both distance and near visual acuity following treatment.  The left eye, rendered completely aniridic by prior surgery, eliminated the possibility of pupil constriction or a pinhole optical effect.  Nevertheless, visual acuity improved from approximately 20/100 to 20/50, and near acuity from 20/70 to 20/30, following bilateral treatment.  Because pupillary mechanisms were anatomically impossible in this eye, these improvements must arise from neural or physiological retinal modulation rather than an optical change.

The temporal profile of improvement further supports a non-optical explanation.  Initial unilateral therapy produced modest gains that stabilized after several weeks, followed by additional improvement when bilateral treatment was introduced at approximately two months.  Optical mechanisms such as miosis generate immediate effects that do not exhibit delayed enhancement or interocular transfer.  In contrast, the delayed and sustained improvements observed here are consistent with adaptive neural processes - Including synaptic plasticity, gain modulation, and perceptual learning.^4,5,6

The bilateral nature of the response offers further evidence for a neural mechanism.  Sequential treatment resulted in improvement of the fellow (right) eye to 20/25, despite initial unilateral application.  Such interocular effects cannot be explained by localized optical phenomena and instead suggest network-level processing or central integration.  These findings raise the possibility that cholinergic modulation influences binocular coordination or higher-order visual processing via retinal ganglion cell projections or corticofugal feedback pathways.⁴

Patient 12 provides an additional internal reference against a pinhole mechanism.  Upon resumption of therapy after improper morning dosing, the restored visual benefit remained partially diminished.  If the improvements were purely optical, the effect of a constricted pupil would be expected to remain constant rather than permanently reduced, further supporting a neurophysiologic basis.

These clinical observations align with current knowledge of retinal neurobiology.  In outer retinal diseases, the inner retina (bipolar, amacrine and ganglion cells) often remains structurally preserved.⁷  Pharmacologic inhibition of acetylcholinesterase increases acetylcholine availability, thereby potentiating cholinergic neurotransmission through nicotinic and muscarinic receptors.  This modulation can enhance signal gain and improve downstream visual processing within remaining neural circuits.^5,6  By augmenting these preserved networks, cholinergic modulation may enable more effective transmission and interpretation of degraded photoreceptor input.^3,8

Alternative explanation - such as subtle optical influences, placebo response, or measurement variability - are unlikely to account for the magnitude, reproducibility, and bilateral pattern of improvement observed, particularly in the absence of an iris and under conditions of pharmacologically reversed miosis.  While the absence of randomization limits definitive conclusions, the use of phenylephrine-induced redilation and inclusion of aniridic control subjects substantially mitigates this limitation.

Taken together, these findings support a model in which topical physiologic/pharmacologic cholinergic modulation enhances visual function through neural mechanisms involving preserved inner retinal and possibly central visual pathways.  This suggests the benefit of a conceptual shift in treatment strategies for outer retinal diseases - from exclusive efforts at replacement therapies such as stem cell or gene therapy - toward additional functional enhancement of surviving neural circuits using pharmacologic therapies.